Document is current

Article History

Received: 2 May 2024

Accepted: 16 January 2025

First Online: 25 January 2025

Declarations

:

: The University of Michigan Institutional Review Board (IRB) approved all study methods and procedures under HUM00231159. Participants received up to $200 for participating in the study, with payment disbursed after each completed survey. This trial was registered to clinicaltrials.gov as NCT06320470.

: All authors approve of this manuscript for publication.

: Dr. Boehnke has received grant funding from Tryp Therapeutics and Journey Biosciences for a clinical trial of psilocybin-assisted therapy and sits on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid). He has received speaking fees for lectures from the Medical Cannabis Research Advocacy Alliance, Provide Holy Cross Medical Center, the Southern Pain Society, and the Michigan Center of Clinical Systems Improvement, and an honorarium for developing a podcast on fibromyalgia with Viatris Inc. Dr. Clauw has received consulting fees from AbbVie, Heron Therapeutics, Aptinyx, Neumentum, Regoneron Pharmaceuticals, Swing Therapeutics, Virios Therapeutics, Allergan Sales, Eli Lilly and Company, H. Lundbeck A/S, Pfizer, Samumed, and Tonix Pharmaceuticals. Dr. Williams has been a consultant for Swing Therapeutics and Community Health Focus. Dr. Litinas has done consulting work with University of Michigan as a subject matter expert, coached and trained consumers and dispensary employees on comprehensive cannabis education, and has a cannabinoid-based product brand. Dr. Bergmans has consulted for Tonix Pharmaceuticals. All other authors declare no conflicts of interest.